Status:
UNKNOWN
Prognosis of Klebsiella ESBL Sepsis: Role of 2-HYDRoxy-myristate in Endotoxin Structure
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Conditions:
Klebsiella Infections
Eligibility:
All Genders
18+ years
Brief Summary
Infections constitute a multiple and heterogeneous set of pathologies, and the first cause of mortality worldwide. Among them, sepsis is a more recent nosological entity, including the most severe for...
Eligibility Criteria
Inclusion
- Patient whose age is ≥ 18 years
- Patient hospitalized in an intensive care unit
- Patient with a nosocomial infection with ESBL-producing Klebsiella
- French-speaking patient
Exclusion
- Patient with a severe psychiatric disorder
- Patient under guardianship or curatorship
- Patient deprived of liberty
- Patient under court protection
- Patient who objects to the use of his or her data for this research
Key Trial Info
Start Date :
October 28 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT05193045
Start Date
October 28 2021
End Date
December 31 2023
Last Update
March 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Paris Saint-Joseph
Paris, France, 75014